Why Bosentan Carries Pregnancy Risks
Bosentan (Tracleer), an endothelin receptor antagonist for pulmonary arterial hypertension, causes serious birth defects and fetal harm. It is pregnancy category X, meaning the risks outweigh any benefits. Animal studies show teratogenicity, embryotoxicity, and fetal death at doses similar to human levels.[1][2]
FDA Black Box Warning Details
The FDA requires a black box warning: Bosentan can cause major birth defects like craniofacial abnormalities, limb defects, and cardiovascular malformations. Women must use two forms of contraception (e.g., hormonal plus barrier) starting one month before treatment, during use, and for one month after stopping. Monthly pregnancy tests are mandatory.[1][3]
What Happens in Exposed Pregnancies
Human data from registries (e.g., PROSPE registry) report high fetal loss rates and malformations in bosentan-exposed pregnancies. No safe dose exists; even brief exposure early in pregnancy risks harm. Live births occur but often with defects.[2][4]
Required Risk Management Program
Bosentan is only available through the REMS program (Tracleer REMS). It mandates:
- Prescriber certification.
- Pharmacy certification.
- Patient enrollment with contraception counseling.
- Negative pregnancy test before first dose.
Failure to comply blocks access.[1][3]
Breastfeeding and Fertility Concerns
Bosentan passes into breast milk and may harm infants; breastfeeding is not recommended. It reduces sperm counts in men, potentially affecting fertility.[1][2]
Alternatives for Women Planning Pregnancy
Switch to safer options like sildenafil or prostacyclins before conception. Discuss with specialists; bosentan requires discontinuation well before trying to conceive.[2]
Sources
[1]: FDA Label for Tracleer (bosentan)
[2]: DrugPatentWatch.com - Bosentan Safety Data
[3]: Tracleer REMS Program
[4]: PROSPE Registry Outcomes